OTC Obesity - Spain

April 2010 | 39 pages | ID: OF0ED900808EN
Euromonitor International Ltd

Abstracts

2009 saw the launch of Alli within Spain. This is the only OTC obesity product available in Spain. In its first year sales of Alli reached a value of EUR9 million.

Euromonitor International's OTC Obesity Products in Spain report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Consumer Health industry;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Executive Summary
Spanish Crisis Damages Sales
Influenza Outbreak
New Leader
Law Shapes Sales
the Recovery
Key Trends and Developments
Spanish Crisis
Global World Favouring Global Diseases
the Silent Pandemic
New Laws Shape Sales
Demographics Still An Issue
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Sales of Consumer Health by Region: Value 2004-2009
  Table 6 Sales of Consumer Health by Region: % Value Growth 2004-2009
  Table 7 Consumer Health Company Shares by Value 2005-2009
  Table 8 Consumer Health Brand Shares by Value 2006-2009
  Table 9 Penetration of Private Label by Sector 2004-2009
  Table 10 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 11 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 12 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 13 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
Consumer Health Registration and Classification
Advertising
Packaging and Labelling
Distribution
De-listing Or De-reimbursement
Vitamins and Dietary Supplements Registration and Classification
Retail Distribution
Self-medication/self-care and Preventative Medicine
Alternative Therapy
Homoeopathic Medicines
Diet Programmes
Local Products
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Almirall Prodesfarma SA
Strategic Direction
Key Facts
  Summary 3 Almirall Prodesfarma SA: Key Facts
  Summary 4 Almirall Prodesfarma SA: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 5 Almirall Prodesfarma SA: Competitive Position 2009
Bayer Hispania SA
Strategic Direction
Key Facts
  Summary 6 Bayer Hispania SA: Key Facts
  Summary 7 Bayer Hispania: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 8 Bayer Hispania SA: Competitive Position 2008
Bicentury Sl
Strategic Direction
Key Facts
  Summary 9 Bicentury SL: Key Facts
  Summary 10 Bicentury SL: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 11 Bicentury SL: Competitive Position 2009
Boehringer Ingelheim España SA
Strategic Direction
Key Facts
  Summary 12 Boehringer Ingelheim España SA: Key Facts
  Summary 13 Boehringer Ingelheim España SA: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 14 Boehringer Ingelheim España SA: Competitive Position 2009
Esteve SA
Strategic Direction
Key Facts
  Summary 15 Esteve SA: Key Facts
  Summary 16 Esteve SA: Operational Indicators
Production
Competitive Positioning
  Summary 17 Esteve SA: Competitive Position 2009
Laboratorios Viñas SA
Strategic Direction
Key Facts
  Summary 18 Laboratorios Viñas SA: Key Facts
Company Background
Production
Competitive Positioning
  Summary 19 Laboratorios Viñas SA: Competitive Position 2009
Mcneil Iberica Slu
Strategic Direction
Key Facts
  Summary 20 McNeil Iberica SLU: Key Facts
Company Background
Production
Competitive Positioning
  Summary 21 McNeil Iberica SLU: Competitive Position 2009
Novartis Farmaceutica SA
Strategic Direction
Key Facts
  Summary 22 Novartis Farmacéutica SA : Key Facts
  Summary 23 Novartis Farmacéutica SA: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 24 Novartis Farmacéutica SA: Competitive Position 2009
Rovi SA
Strategic Direction
Key Facts
  Summary 25 Rovi SA: Key Facts
  Summary 26 Rovi SA: Operational Indicators
Company Background
Production
Competitive Positioning
Uriach-aquilea OTC Sl
Strategic Direction
Key Facts
  Summary 27 Uriach-Aquilea OTC SL: Key Facts
  Summary 28 Uriach-Aquilea OTC SL: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 29 Uriach-Aquilea OTC SL: Competitive Position 2009
Trends
Category Data
  Table 14 Sales of OTC Obesity: Value 2009
  Table 15 OTC Obesity Company Shares by Value 2005-2009
  Table 16 OTC Obesity Brand Shares by Value 2006-2009
  Table 17 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 18 Forecast Sales of OTC Obesity: % Value Growth 2009-2014